| Assessment Status | Rapid Review complete |
| HTA ID | 24019 |
| Drug | Artesunate |
| Brand | Artesunate Amivas® |
| Indication | For the initial treatment of severe malaria in adults and children. |
| Assessment Process | |
| Rapid review commissioned | 29/05/2024 |
| Rapid review completed | 26/06/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that IV Artesunate Amivas® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. February 2025
